Postmarketing Surveillance data
The following events have been reported in association with cabergoline: cardiac valvulopathy and extracardiac fibrotic reactions (see WARNINGS, Cardiac Valvulopathy and Extracardiac Fibrotic Reactions).
Other events have been reported in association with cabergoline: hypersexuality, increased libido and pathological gambling (see PRECAUTIONS, Psychiatric). In addition, cases of alopecia, aggression and psychotic disorder have been reported in patients taking cabergoline. Some of these reports have been in patients who have had prior adverse reactions to dopamine agonist products.
Overdosage might be expected to produce nasal congestion, syncope, or hallucinations. Measures to support blood pressure should be taken if necessary.
The recommended dosage of cabergoline tablets for initiation of therapy is 0.25 mg twice a week. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient’s serum prolactin level. Before initiating treatment, cardiovascular evaluation should be performed and echocardiography should be considered to assess for valvular disease.
Dosage increases should not occur more rapidly than every 4 weeks, so that the physician can assess the patient’s response to each dosage level. If the patient does not respond adequately, and no additional benefit is observed with higher doses, the lowest dose that achieved maximal response should be used and other therapeutic approaches considered. Patients receiving long term treatment with cabergoline should undergo periodic assessment of their cardiac status and echocardiography should be considered.
After a normal serum prolactin level has been maintained for 6 months, cabergoline may be discontinued, with periodic monitoring of the serum prolactin level to determine whether or when treatment with cabergoline should be reinstituted. The durability of efficacy beyond 24 months of therapy with cabergoline has not been established.
Cabergoline tablets are white, capsule-shaped, flat, scored tablets containing 0.5 mg cabergoline. Each tablet is engraved “APO” on one side and “CA” bisect “0.5” on the other side.
Cabergoline tablets are available as follows:
Bottles of 8 tablets NDC 60505-2597-2
Store at controlled room temperature 20° to 25° C (68° to 77° F) [see USP].
APOTEX INC. CABERGOLINE TABLETS 0.5 mg
|Manufactured by||Manufactured for|
|Apotex Research Pvt. Ltd.||Apotex Corp.|
|Bangalore — 560 099||Weston, Florida|
Revised: October 2016
APOTEX CORP. NDC 60505-2597-2
| CABERGOLINE |
|Labeler — Apotex Corp. (845263701)|
|Registrant — Apotex Inc. (209429182)|
|Apotex Research Private Limited||862584104||analysis (60505-2597), manufacture (60505-2597)|
Revised: 05/2017 Apotex Corp.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.